Question

explain the table 1 and figure 2. what question is being asked and table 1 and figure 2.

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis TABLE 1 Base-Case Estimates of Cost, OALYS, and incremental Cost-Effectiveness with 10-Year Time Horizon Cost $ QALYS ICER, S/QALY ICER vs. Etanercept, S/QALY No treatment 00.451 5531 - N/A N/A Apremilast 137,080 6.403 81,033 (vs. no treatment NA Etanercept 1887 6.505 433 248 Vs apremilast N/A Adalimumab 194.180 6681 72.703 vs tanercepe 72.70) Infliximab 176,695 6 804 Dominant Dominant Ustekinumab 255,422 6.959 Dominated 162923 Secukinumab 208,727 7045 132.91) (vs. infliximab) 50 661 Brodalumab 236,690 7.173 217.589 vs. secukinumab) 82.766 Exekizumab 208,872_(vs. brodalumab) 89,991 ICER = incremental cost-effectiveness ratio, NIA not applicable, QALY-quality-adjusted life-year 1938

Answer 1

The table 1 depicts the nine different parameters and it's costs , quality adjusted life year , ICER / QALY and ICER vs Etanercrept / QALY .

Figure 2 is the graphical representation of the above table in which two parameters which are taken into consideration is the 10 year cost for plaque psoriasis and how it affects the quality - of life (over 10 year )